Hematologic neoplasms, blood cancer research hub

A study of JNJ-95804306 for relapsed or refractory hematological malignancies

This early-stage clinical trial is testing a new medicine called JNJ-95804306 for adults with blood cancers that have returned or stopped responding to standard treatments. Doctors want to find safe doses and check how well the body handles the drug when given alone or with other cancer therapies.